Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 1, 2010, Pages 413-417

  Kim, Hee Jin ^a   Jung, Myung Ho ^a   Kim, Hwan ^a   El Gamal, Mohammed I ^a   Sim, Tae Bo ^a   Lee, So Ha ^a   Hong, Jun Hee ^c   Hah, Jung Mi ^a   Cho, Jung Hyuck ^a   Choi, Jung Hoon ^b   Yoo, Kyung Ho ^a   Oh, Chang Hyun ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Hanyang University   (South Korea)

^c Chosun University   (South Korea)

Author keywords

A375; Antiproliferative activity; HS 27; Melanoma; Pyrrolo 3,2 b pyridine

Indexed keywords

PYRIDINE DERIVATIVE; PYRROLO[3,2 B]PYRIDINE DERIVATIVE; SORAFENIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MELANOMA;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL LINE; HUMANS; MELANOMA; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 72049089544     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.08.005     Document Type: Article

References (25)

1. Atallah E., and Flaherty L. Curr. Treat. Options Oncol. 6 (2005) 185
2. Barth A., Wanek L.A., and Morton D.L. J. Am. Coll. Surg. 181 (1995) 193
3. Anderson C.M., Buzaid A.C., and Legha S.S. Oncol. (Williston Park) 9 (1995) 1149
4. Gray-Schopfer V., Wellbrock C., and Marais R. Nature 445 (2007) 851
5. Garbe C., and Eigentler T.K. Melanoma Res. 17 (2007) 117
6. Koon H.B., and Atkins M.B. Expert Rev. Anticancer Ther. 7 (2007) 79
7. Lawson D.H. Cancer Control 12 (2005) 236
8. Rosenburg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C.A., and White D.E. Ann. Surg. 210 (1989) 474
9. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., and Rosenberg S.A. J. Clin. Oncol. 17 (1999) 2105
10. Wilhelm S.M., Carter C., Tang L., Wilkie D., Mcnabola A., and Rong H. Cancer Res. 64 (2004) 7099
11. Strumberg D., Richly H., Hilger R.A., Schleucher N., and Korfee S. J. Clin. Oncol. 23 (2005) 965
12. Clark J.W., Eder J.P., Ryan D., Lathia C., and Lenz H.J. Clin. Cancer Res. 11 (2005) 5472
13. Hirte H.W., Moore M., Siu L., Oza A., and Hotte S.J. Ann. Oncol. 16 (2005) 1688
14. Strumberg D., Voliotis D., Moller J.G., Hilger R.A., Richly H., and Kredtke S. J. Clin. Pharmacol. Ther. 40 (2002) 580
15. Richly H., Kupsh P., Passage K., Grubert M., Voigtmann R., and Schwartz B. Int. J. Clin. Pharmacol. Ther. 42 (2004) 650
16. Wood, J. E.; Wild, H; Rogers, D. H.; Lyons, J.; Katz, M. E.; Caringal, Y. V. PCT Pat. Appl. WO 98052559, May 23, 1997.
17. Bankston D., Dumas J., Natero R., Riedl D.R., and Monahan M.-K. Org. Process Res. Dev. 6 (2002) 777
18. Khire U.R., Bankston D., Barbosa J., Brittelli D.R., Caringal Y., and Carlson R. Bioorg. Med. Chem. Lett. 14 (2004) 783
19. Wan P.T.C., Garnett M.J., Roe S.M., Lee S., and Niculescudunaz D. Cell 116 (2004) 855
20. Nam B.S., Kim H., Oh C.-H., Lee S.H., Cho S.J., Sim T.B., Hah J.-M., Kim D.J., Choi J.H., and Yoo K.H. Bioorg. Med. Chem. Lett. 19 (2009) 3517
21. Li H.-F., Lu T., Zhu T., Jiang Y.-J., Rao S.-S., Hu L.-Y., Xin B.-T., and Chen Y.-D. Eur. J. Med. Chem. 44 (2009) 1240
22. David J.A., Robert A.E., Diane E.F., and Ben Z. Org. Process Res. Dev. 8 (2004) 62
23. 50 was calculated using GraphPad Prism 4.0 software.
24. Eisen T., Ahmad T., Flaherty K.T., Gore M., Kaye S., Marais R., Gibbens I., Hackett S., James M., Schuchter L.M., Nathanson K.L., Xia C., Simantov R., Schwartz B., Poulin-Costello M., O'Dwyer P.J., and Ratain M.J. Br. J. Cancer 95 (2006) 581
25. 3 599.2144, found 599.2143.